Patent 6297213 Issued on October 2, 2001. Estimated Expiration Date: May 7, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/12, 25 or more peptide repeating units in known peptide chain structure424/423, Surgical implant or material424/426, Errodable, resorbable, or dissolving514/2, Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI530/350, PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES530/395Glycoprotein, e.g., mucins proteoglycans, etc.
Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using recombinant DNA technology, and 4) osteogenically and chondrogenically active synthetic protein constructs.
Canalis et al. (1980) Science 210: 1021-1023 "Stimulation of DNA and Collagen Synthesis by Autologous Growth Factor in Cultured Fetal Rat Calvaria.
Glowacki et al. (1981) Lancet 1:959-963 "Application of the Biological Principle of Induced Osteogenesis for Craniofacial Defects.
Reddi (1981) Collage Rel. Res. 1:209-226 "Cell Biology and Biochemistry of Endochondral Bone Development.
Sampath et al. (1981) Proc. Natl. Acad. Sci. USA 78:7599-7603 "Dissociative Extraction and Reconstitution of Extracellular Matrix Components Involved in Local Bone Differentiation.
Farley et al. (1982) Biochem. 21:3508-3513 "Human Skeletal Growth Factor: Characterization of Mitogenic Effect on Bone Cells In Vitro.